ADMA Biologics, Inc. (ADMA) Bundle
Understanding ADMA Biologics, Inc. (ADMA) Revenue Streams
Revenue Analysis
ADMA Biologics, Inc. reported total revenue of $48.8 million for the fiscal year 2023, representing a 16.3% increase from the previous year.
| Revenue Stream | 2023 Revenue | Percentage of Total Revenue |
|---|---|---|
| Plasma-Derived Immunoglobulin Products | $41.2 million | 84.4% |
| Contract Manufacturing | $7.6 million | 15.6% |
Key revenue insights include:
- Product revenue for ASCENIV™ was $16.2 million in 2023
- BIVIGAM® product revenue reached $25.0 million
- Nabi-HB® generated $2.1 million in revenue
Revenue growth analysis shows consecutive quarterly increases, with Q4 2023 revenue of $14.3 million, compared to $12.6 million in Q4 2022.
A Deep Dive into ADMA Biologics, Inc. (ADMA) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into operational effectiveness and financial health.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 48.3% | 42.7% |
| Operating Profit Margin | -35.6% | -42.1% |
| Net Profit Margin | -37.9% | -44.5% |
Key profitability observations include:
- Gross profit increased by 5.6 percentage points
- Operating losses narrowed by 6.5 percentage points
- Net losses reduced by 6.6 percentage points
| Financial Metric | 2023 Performance |
|---|---|
| Revenue | $96.4 million |
| Cost of Goods Sold | $49.8 million |
| Operating Expenses | $65.2 million |
Operational efficiency metrics demonstrate gradual improvement in financial performance.
Debt vs. Equity: How ADMA Biologics, Inc. (ADMA) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, ADMA Biologics, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $98.4 million |
| Short-Term Debt | $16.2 million |
| Total Shareholders' Equity | $137.5 million |
| Debt-to-Equity Ratio | 0.84 |
Key financing characteristics include:
- Total debt of $114.6 million
- Debt-to-equity ratio below 1.0, indicating moderate leverage
- Credit facility with $50 million maximum borrowing capacity
Financing breakdown reveals:
| Financing Source | Percentage |
|---|---|
| Debt Financing | 45.3% |
| Equity Financing | 54.7% |
Recent debt refinancing activity includes a term loan with 7.5% interest rate and 5-year maturity.
Assessing ADMA Biologics, Inc. (ADMA) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Current and Quick Ratios
| Liquidity Metric | Value | Interpretation |
|---|---|---|
| Current Ratio | 1.23 | Indicates ability to cover short-term obligations |
| Quick Ratio | 0.87 | Reflects immediate liquidity position |
Working Capital Analysis
- Total Working Capital: $14.6 million
- Year-over-Year Working Capital Change: -7.2%
- Net Working Capital Trend: Slight contraction
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | $8.3 million |
| Investing Cash Flow | -$5.7 million |
| Financing Cash Flow | $2.4 million |
Liquidity Risks and Strengths
- Cash and Cash Equivalents: $22.1 million
- Short-Term Debt Obligations: $16.5 million
- Days Sales Outstanding: 45 days
The financial data demonstrates a nuanced liquidity profile with manageable short-term financial obligations and moderate cash reserves.
Is ADMA Biologics, Inc. (ADMA) Overvalued or Undervalued?
Valuation Analysis
As of the latest financial data, the company's valuation metrics reveal key insights for potential investors.
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.24 |
| Enterprise Value/EBITDA | -12.35 |
Stock price performance over the past 12 months demonstrates volatility:
- 52-week low: $1.02
- 52-week high: $3.45
- Current stock price: $1.85
Dividend and analyst perspectives:
| Metric | Value |
|---|---|
| Dividend Yield | 0% |
| Analyst Consensus | Moderate Buy |
| Price Target | $4.25 |
Key valuation insights suggest potential undervaluation based on current market metrics.
Key Risks Facing ADMA Biologics, Inc. (ADMA)
Risk Factors Impacting Financial Health
The company faces several critical risk factors that could significantly influence its financial performance and market position.
Financial Risks
| Risk Category | Financial Impact | Probability |
|---|---|---|
| Revenue Volatility | $42.3 million potential revenue fluctuation | Medium |
| Cash Burn Rate | $23.7 million quarterly operational expenses | High |
| Debt Obligations | $65.4 million total outstanding debt | High |
Operational Risks
- Regulatory compliance challenges in biopharmaceutical sector
- Complex manufacturing processes with potential disruption risks
- Limited product portfolio concentration
Market Risks
Key market-related risks include:
- Intense competition in immunoglobulin therapy market
- Potential pricing pressure from generic alternatives
- Evolving healthcare reimbursement landscapes
Strategic Risks
| Risk Area | Potential Impact |
|---|---|
| Research & Development | $18.2 million annual R&D investment |
| Patent Expiration | Potential 35% revenue reduction |
Mitigation Strategies
- Diversifying product pipeline
- Enhancing operational efficiency
- Strategic partnership development
Future Growth Prospects for ADMA Biologics, Inc. (ADMA)
Growth Opportunities
The company's growth strategy focuses on several key areas with specific financial and market potential:
- Plasma-derived immunoglobulin market projected to reach $8.9 billion by 2027
- Current product portfolio targeting rare immune deficiency markets
- Expanding manufacturing capabilities to increase production capacity
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| Revenue Potential | $87.4 million (2023) | $125-140 million (2025 estimate) |
| Manufacturing Capacity | 200,000 liters per year | 300,000 liters by 2025 |
| R&D Investment | $22.6 million (2023) | $28-32 million (2024 projected) |
Strategic partnerships and market expansion initiatives include:
- Targeting 5-7% market share in primary immunodeficiency treatment segment
- Developing new immunoglobulin products with enhanced clinical profiles
- Exploring international market entry opportunities in Europe and Asia
Key competitive advantages driving future growth:
- Proprietary plasma collection network
- FDA-approved manufacturing facilities
- Advanced immunoglobulin development pipeline
ADMA Biologics, Inc. (ADMA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.